GlassScriptPhysician profile
Ashim K Dayalan
NPI 1376508028
$25,683.80
in general payments reported to CMS, 2019-2025
62 companies · $3,846 in 2025
The $3,846 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,342 · 2020: $3,084 · 2021: $4,661 · 2022: $3,132 · 2023: $3,411 · 2024: $4,208 · 2025: $3,846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $41.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,423.26 |
| Education | $41.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,473.41 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $3,465.24 | 2019-2025 | Vraylar, Ubrelvy, Linzess |
| Astrazeneca Pharmaceuticals LP | $2,161.95 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $1,809.43 | 2019-2025 | Spravato, Xarelto |
| Glaxosmithkline, LLC. | $1,490.90 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,465.80 | 2019-2025 | Jardiance, Synjardy |
| Amgen INC. | $1,444.00 | 2019-2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $1,135.39 | 2019-2025 | |
| Daiichi Sankyo INC. | $710.03 | 2019-2024 | Vanflyta, Injectafer |
| Lilly USA, LLC | $696.47 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Abbott Laboratories | $581.93 | 2020-2025 | Proclaim, Freestyle Libre 3, Penta |
| Novartis Pharmaceuticals Corporation | $513.58 | 2019-2025 | |
| Allergan, INC. | $477.27 | 2019-2021 | |
| Amarin Pharma, INC. | $426.00 | 2019-2021 | |
| Orexo US, INC. | $397.32 | 2019-2025 | Zubsolv |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $320.93 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $292.36 | 2019-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $277.41 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| E.R. Squibb & Sons, L.L.C. | $264.62 | 2019-2025 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $253.19 | 2021-2024 | |
| Amneal Pharmaceuticals LLC | $245.95 | 2021-2025 | Unithroid |
| Cequr Corporation | $235.20 | 2022-2025 | Cequr Simplicity |
| Astellas Pharma US INC | $225.84 | 2019-2025 | Veozah, Myrbetriq |
| Shield Therapeutics INC | $221.05 | 2023-2025 | Accrufer |
| Medtronic, INC. | $204.76 | 2021-2025 | Inpen Smart Insulin Delivery System, Minimed 780g |
| Phathom Pharmaceuticals, INC. | $204.11 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $162.03 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $148.15 | 2022 | |
| Idorsia Pharmaceuticals US INC | $145.20 | 2022-2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $140.24 | 2022-2025 | Zoryve, Seglentis |
| Ironwood Pharmaceuticals, INC | $133.70 | 2020-2022 | |
| Radius Health, INC. | $130.96 | 2019-2022 | |
| Axsome Therapeutics, INC. | $126.73 | 2025 | Symbravo |
| Lundbeck LLC | $124.38 | 2023-2025 | Vyepti, Rexulti |
| Dexcom, INC. | $120.58 | 2021-2025 | Dexcom G6 Transmitter |
| Scilex Pharmaceuticals INC. | $103.95 | 2019 | |
| Sanofi-Aventis U.S. LLC | $103.22 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.62 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Teva Pharmaceuticals USA, INC. | $94.64 | 2020-2025 | Austedo Xr |
| Currax Pharmaceuticals LLC | $89.93 | 2022-2025 | Contrave, Onzetra Xsail, Nexletol |
| Xeris Pharmaceuticals, INC. | $89.37 | 2024-2025 | Gvoke Hypopen |
| Esperion Therapeutics, INC. | $83.70 | 2021-2024 | Nexletol |
| Biohaven Pharmaceuticals, INC. | $75.23 | 2021 | |
| Eisai INC. | $71.76 | 2021-2024 | |
| Braeburn INC. | $69.49 | 2024-2025 | Brixadi |
| Ibsa Pharma INC. | $65.31 | 2019-2020 | |
| Medtronic Minimed, INC. | $62.13 | 2019 | |
| Almatica Pharma LLC | $50.69 | 2021-2023 | Gralise, Loreev Xr, Sertraline Hcl |
| Tosoh Bioscience, INC. | $47.00 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $44.41 | 2023 | Opsumit, Uptravi |
| Indivior INC. | $42.29 | 2024-2025 | Sublocade |
| Boston Scientific Corporation | $38.14 | 2021-2024 | Watchman Flx |
| Corcept Therapeutics | $33.67 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $32.12 | 2024 | Rexulti |
| Inspire Medical Systems, INC. | $26.34 | 2025 | Inspire |
| Beta Bionics, INC. | $23.37 | 2024 | Ilet Bionic Pancreas |
| Alvogen INC | $22.67 | 2025 | Teriparatide |
| Nevro Corp. | $22.29 | 2021 | |
| Acadia Pharmaceuticals INC | $20.79 | 2025 | Daybue |
| Ultragenyx Pharmaceutical INC. | $16.04 | 2022 | |
| Tactile Systems Technology INC | $15.76 | 2023 | Flexitouch Plus, Entre Plus |
| Biodelivery Sciences International, INC. | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashim Dayalan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.